Subsequently, however, generation of the APCmin  bigenic mouse with an intestinal-specific PPAR-γ deficiency demonstrated unequivocally that PPAR-γ suppresses tumor formation and suggested that thiazolidinedione has significant off-target effects in mice, especially in the APCmin  mouse colon cancer model [111]. This evidence concerns the gene PPARG and colonic neoplasm.